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Abstract 
 
Colorectal cancer (CRC) remains a serious health concern, being the third most 
commonly diagnosed cancer and the fourth leading cause of cancer-related death in 
Europe. In Portugal, CRC is both the most frequently diagnosed and the one that causes 
more cancer-related deaths. The incidence of this disease increased in the last thirty years 
and it is expected to rise by 60% to more than 2.2 million new cases and 1.1 million 
cancer deaths by 2030.  
  Despite advances in diagnosis and treatment, up to 20% of stage II CRC patients 
subjected to tumor resection with curative intent develop disease recurrence. The 
therapeutic approach after surgery is yet not consensual, nor effective, and depends to a 
large extent on disease staging. It would be desirable to have both prognostic biomarkers, 
that stratify better the patients and thus help to identify who should be treated, and 
predictive biomarkers, that foretold the likelihood of the benefit of administering a 
specific chemotherapeutic drug to cancer patients.  
With this project, we intend to improve scientific insight into new molecular 
parameters that could help to distinguish specific subgroups of CRC stage II patients and 
foresee which can effectively benefit from current adjuvant therapy treatments. For this 
purpose, in our 230 stage II CRC patient cohort, we investigated by 
immunohistochemistry the biomarker potential of 3 transcription factors - CDX2, SOX2, 
SOX9 - and also microsatellite status, by analysis of expression of the mismatch repair 
proteins. We have also assessed BRAFV600E mutation status by Sanger Sequencing. 
In our CRC series, low CDX2 expression and de novo SOX2 expression 
significantly correlated with less tumor differentiation. SOX2 expression showed 
prognostic value but when considering only cases negative for SOX9. In this case, SOX2 
expression resulted in worst disease-free survival. Moreover, in patients treated with 
adjuvant chemotherapy, de novo SOX2 expression significantly correlated with worse 
patient outcome (P<0.01). For further validation of SOX2 as a predictive biomarker of 
resistance to therapy, we tested the viability of a CRC cell line treated with 5-FU, after 
up- and down-regulation of SOX2 expression but unfortunately, we did not observe 
significant differences. Despite this, previous results from our research group in a 
different intestinal cellular model had already suggested that 5-FU therapy resistance is 
at least partially mediated by SOX2. For that reason, our observations in the retrospective 
study deserve to be further exploited in the near future.  
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Resumo 
O cancro colorectal permanece uma enorme preocupação de saúde, sendo o 
terceiro cancro mais diagnosticado e o quarto responsável pelo maior número de mortes 
por cancro na Europa. Em Portugal, o cancro colorectal é simultaneamente o mais 
diagnosticado e o mais letal. A incidência desta doença aumentou nos últimos 30 anos e 
espera-se que aumente cerca de 60%, com mais de 2,2 milhões de novos casos e 1,1 
milhões de mortes em todo o mundo até 2030.  
Apesar dos avanços no diagnóstico e no tratamento, cerca de 20% dos pacientes, 
diagnosticados com cancro colorectal no estadio II, apesar de sujeitos a cirurgia com 
intenção curativa, relapsam. Atualmente, a decisão sobre a administração de 
quimioterapia adjuvante após a cirurgia não é nem consensual, nem eficaz, e baseia-se 
sobretudo no estadiamento da doença. Seria uma mais valia a existência de biomarcadores 
de prognóstico para estratificar os pacientes e ajudar a decidir quem deve ser tratado, e 
biomarcadores preditivos, que previssem o benefício efetivo da administração de 
determinado quimioterápico. 
Com este projeto o nosso objetivo é ampliar o conhecimento científico atual 
relativamente a potenciais marcadores moleculares que consigam estratificar os pacientes 
e antecipar quais irão efetivamente beneficiar da quimioterapia adjuvante atual. Para isso 
investigámos, por imunohistoquímica, na nossa série de 230 pacientes com cancro 
colorectal no estadio II, o potencial biomarcador de 3 fatores de transcrição - CDX2, 
SOX9 e SOX2 e da instabilidade de microssatélites, por análise de expressão das 
proteínas de mismatch repair. Para além disso pesquisámos a presença da mutação 
BRAFV600E por sequenciação de Sanger.  
Na nossa série de carcinomas colorectais, a baixa expressão de CDX2 e a 
expressão de novo de SOX2 correlacionaram significativamente com uma menor 
diferenciação do tumor. A expressão de SOX2 demonstrou valor prognóstico apenas para 
os casos negativos para o SOX9. Nestes casos, a expressão de SOX2 resultou numa maior 
probabilidade de recidiva. Para além disso, em pacientes tratados com quimioterapia 
adjuvante, a expressão de novo de SOX2 correlacionou significativamente com um pior 
prognóstico dos doentes (p<0.01). Para validar o SOX2 como biomarcador preditivo de 
resposta à terapia, testámos a viabilidade de uma linha celular de carcinoma colorectal 
após silenciamento e sobre-expressão de SOX2, mas infelizmente não se observaram 
diferenças significativas. No entanto, resultados obtidos anteriormente pelo nosso grupo 
de investigação num modelo celular intestinal diferente já tinham sugerido que a 
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resistência ao 5-FU seria, pelo menos parcialmente, mediada pelo SOX2. Por essa razão, 
as nossas observações neste estudo retrospetivo merecem continuar a ser investigadas 
num futuro próximo.  
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Figure 1. Five most incident and most mortal cancers worldwide; both sexes. Data from the GLOBOCAN 
2012 (Ferlay et al., 2013). 
Figure 2. Five most incident and most mortal cancers in Portugal; both sexes. Data from the GLOBOCAN 
2012 (Ferlay et al., 2013). 
 
 
I. Introduction 
 
1.1. Colorectal Cancer 
1.1.1. Incidence and mortality 
Colorectal cancer (CRC) remains a serious health concern, being the third most 
commonly diagnosed cancer and the fourth leading cause of cancer-related deaths 
worldwide (see Figure 1) (Ferlay et al., 2013). In Portugal, CRC is both the most 
frequently diagnosed and the most lethal (see Figure 2) (Ferlay et al., 2013).  
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The incidence of CRC increased in the last thirty years, strongly linked to changes 
in lifestyle and increased exposure to carcinogens, and it is expected to rise by 60% to 
more than 2.2 million new cases and 1.1 million cancer deaths by 2030 (Ferlay et al., 
2013). The American Cancer Society recommend that people at average risk of CRC start 
regular screening at the age of 45. For CRC screening, people are considered to be at 
average risk if they do not have: family or personal history of CRC or else confirmed or 
suspected hereditary CRC syndromes; personal history of adenomatous polyps, 
inflammatory bowel disease or previous treatment with radiation to the abdomen or pelvic 
area to treat a prior cancer.  
 
1.1.2. Colorectal cancer aetiology 
            The majority of CRC, approximately three-quarters, are sporadic (Kuipers et al., 
2015). The most common syndrome of hereditary CRC is the Lynch syndrome which is 
caused by a mutation in one of the DNA mismatch repair genes. The second most 
common CRC syndrome is familial adenomatous polyposis which is caused by mutations 
in the adenomatous polyposis coli (APC) gene, known to control the activity of the 
Wnt/β-catenin signalling pathway. Other hereditary syndromes include polyposis 
associated with mutations in the mutY DNA glycosylase (MUTYH) gene, Peutz-Jeghers 
syndrome, serrated polyposis and juvenile polyposis (Kuipers et al., 2015; Vasen et al., 
2015). 
            The environmental and genetic factors that cause CRC promote genomic 
instability, which is characterized by various genetic and epigenetic alterations leading to 
stimulation of oncogenes and inactivation of tumor suppressor genes (Cuyle et al., 2017). 
Accumulation of mutations in critical genes involved in regulating cellular proliferation, 
differentiation and death provide neoplastic cells with a survival advantage over the 
surrounding normal intestinal epithelium (Punt et al., 2017) causing abnormal expansion 
of the malignant tissue into high grade dysplasia adenomatous polyps which have full 
potential to transform into invasive carcinomas with additional genetic aberrations 
(Markowitz et al., 2009; Punt et al., 2017). 
This traditional adenoma-carcinoma sequence (depicted in Figure 3) is thought to 
be responsible for up to 60% of sporadic CRC (Punt et al., 2017; Tong et al., 2017) and 
emerging evidence supports that some may evolve via alternate pathways, namely  
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Figure 3. Traditional adenoma to carcinoma sequence.  
from serrated polyps (Hardiman 2018). Serrated polyps represent 5 to 10% of all polyps. 
These arise by molecular and histological events distinct from classical tubular adenomas. 
These polyps have the potential to transform through the following sequence: 
hyperplastic polyp to sessile serrated polyp to adenocarcinoma (Rex et al., 2012; Kuipers 
et al., 2015).  
 
 
 
The order in which mutations accumulate during CRC progression is not random 
and the association between these and specific histopathological disease stages has been 
central in CRC research for many years (Punt et al., 2017). Currently, three distinct 
molecular pathways of CRC pathogenesis are well-described namely: 
▪ Chromosomal Instability (CIN) pathway: the majority of CRCs develop through this 
pathway; key changes in CIN cancers include widespread alteration in chromosome 
number and frequent detectable losses at molecular level of portions of chromosomes 
causing genomic instability. 
▪ Microsatellite Instability (MSI) pathway: subset of 10-15% of CRCs that exhibit 
aberrations in microsatellite repeat sequences; the carcinoma progression in MSI is 
faster than in MSS. 
▪ CpG Island methylator phenotype (CIMP) pathway: associated with MSI tumors and 
BRAFV600E mutation; is the pathway of serrated polyposis.  
However, many other are under investigation (PDQ Cancer Genetics Editorial Board. 
Genetics of Colorectal Cancer (PDQ®): Health Professional Version, 2018). 
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1.1.3. Colorectal cancer staging 
Despite the knowledge that CRC is extremely heterogenous, like many other 
cancers, the tumor-node-metastasis (TNM) staging system (Figure 4) is still used to 
classify CRC.  
 
In a CRC patient, T (extent of the tumor), N (spread to nearby lymph nodes) and 
M (spread to distant sites or metastasis) categories are usually determined right after 
resective surgery by examining the resected tissue. This is likely to be more accurate than 
clinical staging, which considers the results of a physical exam, biopsies and imaging 
tests done before surgery. Once the values for T, N, and M have been determined, they 
are combined to assign an overall stage. It is important also to note that TNM stage is 
determined soon after a cancer is diagnosed and does not change, over time, with disease 
progression. Although information about the current extent of the cancer is added and of 
course, the treatment is adjusted as needed, the cancer is always referred to by the stage 
attributed when diagnosed (American Cancer Society, 2018). 
Figure 4.  American Joint Committee on Cancer Tumor Node Metastasis staging system. Data from 
American Cancer Society, 2018. 
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Lymph nodes are small, bean-shaped collections of immune cells. Many types of 
cancer, including CRC, often spread to nearby lymph nodes before reaching other parts 
of the body. Although still being firmly debated, the lymph node status is still the 
strongest predictor and prognosticator in TMN staging system and it is many times used 
to decide whether to give adjuvant chemotherapy in stage CRC, even though it fails to 
accurately predict disease recurrence in a considerable number of patients (Veen et al., 
2013; Lea et al., 2014; Watson et al., 2016). This happens particularly in Stage II CRC 
in which there is no consensus about when adjuvant chemotherapy is beneficial and when 
should it be recommended, leading to an undertreated Stage II subgroup (Table 1) which 
is still to be molecularly defined. 
 
 
Sometimes other factors may be considered when staging, such as cell type, tumor 
location and tumor grade. The grade of a cancer is a measure of differentiation. In low-
grade (well-differentiated) cancers, the cancer cells look similar to normal tissue cells and 
Table 1.  American Joint Committee on Cancer characterization of stage II Colorectal Cancer. Data from 
American Cancer Society, 2018. 
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tend to grow slowly. However, in high grade (poorly-differentiated) cancers, the cancer 
cells look very abnormal, tend to grow quickly and are often indicative of a worse 
prognosis. Even when the grade does not affect stage it will probably still affect prognosis 
and response to therapy (Edge et al., 2010; American Cancer Society, 2018). 
 
1.1.4. Colorectal cancer treatment 
 For non-metastasized CRC, surgery is the main curative treatment. However, for 
rectal carcinomas, chemotherapy is recommended in some cases (Kuipers et al., 2015). 
Since the 1990s, fluorouracil (5-FU) based postoperative chemotherapy, initially 
fluoropyrimidines and more recently combinations with oxaliplatin (Dienstman et al., 
2015), has been used to reduce the risk of tumor recurrence and improve survival for 
patients with resected CRC cancer. Although disease-free survival (DFS) among patients 
with stage III CRC has increased significantly owing the introduction of new adjuvant 
chemotherapy regimens, this has not been extended to earlier stage CRC patients 
(O’Connor et al., 2011, Dalerba et al., 2016). Despite advances in diagnosis and 
treatment, about 15% to 30% of patients with stage II disease develop recurrent loco-
regional disease or distant metastases within 5 years and their overall survival (OS) is 
around 70% (see Figure 5 and Figure 6) (O’Connel et al., 2004; Punt et al., 2017).  
 
 
 
 
Figure 5.  Overall Survival by Stage in Colon Cancer. Data from American Cancer Society, 2018. 
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Post-operative treatment is always recommended for stage III CRC patients, 
however, the absolute survival benefit in stage II disease is only about 2% to 5% with a 
single 5-FU agent, remaining under debate if these patients have sufficient benefit from 
adjuvant chemotherapy to justify its associated toxicity, inconvenience and costs 
(Dienstman et al., 2015). Currently, the decision of giving adjuvant treatment in stage II 
CRC is recommended to be discussed with patients with one or more high risk features: 
T4 primary tumors; poorly differentiated histology (except if associated with mismatch 
repair deficient tumors; presence of lymphovascular and/or perineural invasion; 
perforation and/or obstruction; close, indeterminate or positive resection margins or less 
than 12 lymph nodes in the surgical resection specimen. These patients are currently 
selected based only in histopathologic characteristics and are believed to derive more 
benefit from adjuvant therapy than patients at low risk of relapse (Cuyle et al., 2017).  
 
1.1.5. Stage II colorectal cancer 
Stage II represents almost a third of all CRC patients (see Figure 7). 
Unfortunately, despite being an early stage, in which patients are expected to have better 
outcomes, stage II patient OS is relatively low and too close to stage III, emphasizing the 
need to better understand this subset of patients so we can enlarge their quality of life. 
Interestingly, in rectal cancer, OS for stage II is even lower than stage III (see Figure 6).  
Figure 6.  Overall Survival by Stage in Rectal Cancer. Data from American Cancer Society, 2018. 
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Moreover, the fact that adjuvant therapy regimens were shown to improve too 
little the outcome of CRC stage II patients, plus that chemotherapy is administered in 
nearly 20% to 59% for stage II CRC patients (Grant et al., 2018) we are led to the 
assumption that there is an extensive risk of non-effective overtreatment. In fact, in the 
QUASAR clinical trial, stage II patients were randomized to either 5-FU based therapy 
or observation and the results demonstrated only 3% improvement in outcome for the 5-
FU-treated patients (Marshall 2010; Watson et al., 2016).  
Furthermore, even current guidelines fail alone to accurately subclassify which 
patients will effectively benefit from adjuvant chemotherapy (O’Connor et al., 2011; 
Dienstmann et al., 2015; Watson et al., 2016). Actually, it has been shown that stage II 
patients receiving adjuvant treatment with any high-risk variable did not have better OS 
than patients with any high-risk variable not receiving adjuvant chemotherapy (O’Connor 
et al., 2011).  
It is obvious the urgent need of validated biomarkers to help overcome the current 
challenge in clinical decision management in stage II CRC. The goal of personalized 
medicine is to provide each patient, based on his individual biomarker characteristics 
beyond the functional diagnosis of his disease, with the right treatment and dose at the 
right time. Therefore, it would be desirable to have both prognostic biomarkers to help 
stratify patients and thus help to identify who should be treated, and predictive biomarkers 
Figure 7.  Colorectal Cancer distribution by stages. Data from American Cancer Society, 2018. 
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that foretold the likelihood of the benefit of administering a specific chemotherapeutic 
drug to cancer patients. In the last years there has been intense investigations for new 
biomarkers. The expectations regarding its potential to upgrade personalized medicine 
are incredibly high, however the pace has been much slower than hoped.   
 
1.1.6. Biomarkers in colorectal cancer 
1.1.6.1. Microsatellite instability (MSI) 
Microsatellite instability (MSI) is a molecular marker of deficient mismatch repair 
(dMMR). Mutations in MMR genes are very common in cancer and lead to a deficient 
elimination of single-base nucleotide sequences (called the “microsatellites”) that occur 
during DNA replication. This allows the accumulation of somatic mutations, therefore 
inducing genomic instability that contributes to tumor development, growth and 
dissemination (Cuyle et al., 2017).  
The dMMR can be investigated by testing the loss of expression of at least one 
MMR protein by immunohistochemistry, or analysing mutations in genes using a PCR-
based assay with a panel of microsatellite markers. Both tests were shown to be highly 
concordant (Sinicrope et al., 2010; Garber 2017). However, neither test is completely 
sensitive, because an MMR gene may be qualitatively, but not quantitatively, changed by 
mutation and thus stain even though it is functionally disabled, while PCR testing for 
microsatellites may miss the defect because the signal is absent due to intratumoral 
heterogeneity (Garber 2017; Punt et al., 2017). 
MSI-High (MSI-H) is a hallmark of Lynch syndrome that, although highly 
penetrant, accounts for less than 5% of all CRCs. MMR testing is part of the guidelines 
to identify the patients which are likely to carry a germline mutation in one of the known 
MMR genes, most commonly MLH1 or MSH2. The majority of MSI-H CRCs, however, 
are sporadic non-Lynch syndrome cases that result from epigenetic inactivation of the 
MLH1 gene promoter by DNA hypermethylation (Sinicrope et al., 2010). 
MSI prevalence is higher in earlier stages of CRC and decreases in advanced 
disease, being two times higher in stage II than stage III CRC (Mouradov et al., 2013). 
Moreover, MSI tumors are more common in elderly patients and in the colon when 
compared to rectum, being particularly frequent in right-sided colon primary tumors 
(Grant et al., 2018). In fact, Sinicrope et al., 2010 found positive prognostic relevance of 
MSI only for right-sided stage II CRC.  
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In stage II CRC, MSI is found in nearly 20% of patients and it has been strongly 
associated with better OS when compared to MSS (microsatellite stable) patients (Merok 
et al., 2013; de Cuba et al., 2016). Furthermore, MSI status is frequently associated with 
BRAF mutation and it is reported to override the poor prognosis associated with this 
mutation. In fact, patients with tumors MSI and BRAF-mutated have good prognosis.  
Other studies have however indicated that MSI CRC patients are less sensitive to 
5-FU based chemotherapy and drive no benefit from it (Ribic et al., 2003; Sinicrope et 
al., 2011; Mouradov et al., 2013; Chen et al., 2016; Puccini et al., 2017). In fact, it is 
becoming increasingly common to test all newly diagnosed cases of CRC for MSI, as it 
serves not only as a screening marker for Lynch Syndrome but also because latest 
guidelines recommend to not administrate adjuvant 5-FU based therapy to MMR-
deficient (MSI) patients (Zarkavelis et al., 2017).  
Nonetheless, in two recent meta-analysis focused strictly on stage II CRC patients, 
MSI status was reported to lack significant prognostic and predictive relevance (Gkekas 
et al., 2017; Romiti et al., 2017). 
 
1.1.6.2. BRAFV600E mutation 
B-Raf proto-oncogene, serine/threonine kinase (BRAF) is one of the main RAF 
family genes, a downstream effector molecule of the KRAS proto-oncogene GTPase and 
it is involved in the progression of several malignancies including CRC (Davies et al., 
2002; Molaei et al., 2016).  
The V600E missense mutation in BRAF accounts for up to 90% of all mutations 
in human cancers (Vogelaar et al., 2015) and it is responsible for the constitutive 
activation of the mitogen-activated protein kinase (MAPK) pathway, known to be one of 
the most critical pathways in the regulation of cancer cell proliferation and survival 
(Molaei et al., 2016). This oncogenic mutation is the most frequent in BRAF gene and 
consists in a transversion between thymine and adenine within codon 600, leading to a 
substitution of a valine by glutamic acid at protein level (Davies et al., 2002; Molaei et 
al., 2016). BRAFV600E mutation is considered as a driver in CRC serrated pathway and 
polyps are considered its precursor lesions, thus defining this mutation as an early event 
in CRC (Barras et al., 2017; Sanz-Garcia et al., 2017). Despite being highly frequent in 
serrated CRC tumors, BRAFV600E has been shown to inefficiently drive tumorigenesis in 
mouse models and to trigger stem cell loss (Tong et al., 2017).  
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There are many evidences in the literature for BRAFV600E as an indicator of poor 
outcome in CRC, however patient categories included in these studies were very 
heterogenous and mostly focused on late stage patients. Moreover, in a recent study that 
grouped differently early- and late-stage CRC patients it was found that only in late-stage 
tumors the mutated BRAF showed a trend to have worse prognosis, when compared with 
BRAF wild-type patients (Chen et al., 2016). Nevertheless, in some studies no prognostic 
role of BRAFV600E mutation has been demonstrated (French et al., 2008; Mouradov et al., 
2013; Andre et al., 2015; Vogelaar et al., 2015). Interestingly, BRAFV600E reported 
frequencies in CRC patients vary a lot between studies. This may be due to the fact that 
rectal cancer patients do not usually harbour this mutation and studies that include a 
higher percentage of rectal cancers may have lower BRAFV600E mutation frequencies 
(Tamas et al., 2015). 
Since BRAF-mutated CRC is often associated with other high-risk 
clinicopathological features such as later age at diagnosis and poorly differentiated 
tumors, it is very difficult to distinguish the actual prognostic influence of the BRAF 
mutation from the interaction with the other poor prognostic characteristics (Andre et al., 
2015; Vogelaar et al., 2015; Cuyle et al., 2017). There is still much controversy in BRAF 
potential as a biomarker, also due to its paradoxically strong association with MSI, which 
is an indicator of good prognosis (Mouradov et al., 2013; Sanz-Garcia et al., 2017). 
BRAFV600E mutation is about 8 times more prevalent in MSI-High as compared with MSS 
tumors (Dienstmann et al., 2017). It has been suggested has BRAF mutation only predicts 
outcome in MSI cases. Interestingly, this association is lost in late stage CRC, reinforcing 
the idea that BRAF mutation has stronger independent prognostic value in later stages of 
CRC (Chen et al., 2016).   
Furthermore, it is important to take into account the relevant molecular 
heterogeneity between BRAFV600E mutated tumors that might translate into clinical 
differences, both in terms of prognosis and sensitivity to chemotherapeutic agents 
(Guinney et al., 2015; Cuyle et al., 2017; Barras et al., 2017; Cremolini et al., 2015).  
 
1.1.6.3. Caudal type homeobox 2 (CDX2) 
The caudal type homeobox 2 transcription factor (CDX2) is a major regulator of 
intestine-specific genes, essential for the balance between cell differentiation and 
proliferation (Zheng et al., 2015) and have a central role in the maintenance of the 
intestinal homeostasis (Lundberg et al., 2016).  
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CDX2 is expressed at high levels in the normal colorectum epithelium, but loss or 
decrease of expression is seen in a subset of CRCs (Lundberg et al., 2016) and has been 
associated with an increased likelihood of aggressive features such as advanced stage and 
BRAFV600E mutation (Baba et al., 2009; De Sousa e Melo et al., 2013; Bae et al., 2015; 
Dalerba et al., 2016; Bruun et al, 2018). 
CDX2 expression is inversely correlated with stem cell properties (Huang et al., 
2017). Accordingly, in CRC, low CDX2 expression has been associated in some studies 
with poor differentiation and poor prognosis. CDX2 expression is predictive of a better 
response to adjuvant chemotherapy (Dalerba et al., 2016; Bruun et al., 2018). However, 
other studies found no prognostic value for CDX2 expression (Olsen et al., 2016; Dawson 
et al., 2014). There is still much controversial data emphasizing the need of further 
studies. 
In vivo studies showed an important role for CDX2 as a tumor suppressor gene in 
the formation and the development of tumors, however its antitumor mechanisms remain 
to be fully elucidated (Takakura et al., 2010; Zheng et al., 2015). 
 
1.1.6.4. Sex-determining region Y-box 2 (SOX2) 
Sex-determining region Y-box 2 (SOX2) is a member of the large SOX gene 
family comprising transcription factors known to be important in the regulation of 
developmental processes and cell type specification (Sarkar et al., 2013; Lundberg et al., 
2014). 
In CRC, SOX2 de novo expression has been associated with poorly differentiated 
plus more invasive tumors and poor OS, especially in BRAFV600E mutated cases 
(Lundberg et al., 2014). However, this prognostic value is stage-dependent and was only 
observed in subsets of patients who did not receive adjuvant therapy (Du et al., 2016). In 
vitro, SOX2 has previously been shown to be expressed at higher levels in drug-resistant 
cells when compared to the parental colon cancer cell line (Yang et al., 2013). 
The fact that SOX2 expression is correlated with poorly differentiated tumors 
seems concordant with the fact that SOX2 is a cancer stem cell marker (Ben-Porath et al., 
2008; Lundberg et al., 2014). SOX2 plays a critical role is cancer stem cells self-renewal, 
affecting tumorigenesis, prognosis and chemoresistance and has been shown to induce in 
vitro a cancer stem cell state in CRC (Lundberg et al., 2016). 
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1.1.6.5. Sex-determining region Y-box 9 (SOX9) 
Sex-determining region Y-box 9 (SOX9) is a transcription factor expressed in the 
highly proliferative compartment of the healthy intestinal epithelium at the bottom of the 
crypts and in Paneth cells (Blache et al., 2004). Current literature pertaining SOX9 role 
in CRC is controversial as it is described to behave both as a tumor suppressor and as an 
oncogene (reviewed in Prévostel et al., 2017). SOX9 was described to be both regulated 
(Blache et al., 2004) and to inhibit the oncogenic Wnt/β-catenin signalling pathway 
(Bastide et al., 2007; Topol et al., 2009; Prévostel et al., 2014). Moreover, SOX9 
conditional knock-out in the mouse intestinal epithelium resulted in increased 
proliferation and decreased differentiation (Bastide et al., 2007; Mori-Akiyama et al., 
2007), while SOX9 overexpression supressed proliferation in the intestine of a transgenic 
mouse model (Formeister et al., 2009). Concordantly, SOX9 overexpression in colorectal 
cancer cells is sufficient to inhibit cell proliferation (Shi et al., 2013; Prévostel et al., 
2014) whereas SOX9 knock-down increases proliferation of human colorectal cancer 
cells (Shi et al., 2013). These results point to a tumor suppressor role of SOX9 in CRC. 
Yet other studies support an oncogenic role for SOX9 by reporting that SOX9 knock-
down results in decrease of proliferation and tumor growth capacity (Matheu et al., 2012; 
Carrasco-Garcia et al., 2016) whereas SOX9 overexpression increases tumorigenic 
potential of CRC cells grafted in mice (Lu et al., 2008).  
Correspondingly, the relevance of SOX9 expression as a possible prognostic 
biomarker is still paradoxical. There are reports correlating both high levels (Lu et al., 
2008) and low levels (Espersen et al., 2016) of SOX9 with poor prognosis in CRC and a 
study enrolling a large number of patients that shows no association with prognosis 
(Bruun et al., 2014).   
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II. Aim 
With this project we intend to improve scientific insight into new molecular 
parameters that could stratify CRC stage II patients in subgroups with different expected 
prognosis and response to current, 5-FU based, adjuvant chemotherapy treatments. 
For this purpose, we aim to evaluate not only the prognostic relevance but also the 
predictive value of a panel of molecules of interest in stage II colorectal carcinoma. More 
specifically, we will analyse microsatellite instability (MSI) and BRAFV600E mutation 
status and the expression of CDX2, SOX2 and SOX9 transcription factors in a series of 
230 Portuguese patients diagnosed with stage II colorectal adenocarcinoma. 
Because we found a significant predictive value for SOX2 expression in our 
retrospective study we further intend to test the viability of a CRC cell line, treated with 
5-FU, after up- and down-regulation of SOX2 expression. 
The specific objectives of this project were: 
▪ To characterize MSI status and BRAFV600E mutation, and to detect the 
expression of CDX2, SOX2 and SOX9 proteins in a stage II CRC Portuguese 
cohort establishing the prevalence of these 5 putative biomarkers in our series. 
▪ To analyse the correlation between our observations and clinicopathological 
features of the tumors, disease-free survival and overall survival, in order to 
assess the relevance of these molecules as predictive and/or prognostic CRC 
biomarkers. 
▪ To modulate SOX2 expression in colon carcinoma cell lines and evaluate their 
viability after treating them with 5-FU, in order to infer about the value of 
SOX2 in 5-FU based chemotherapy resistance. 
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III. Materials and Methods 
3.1. Patients  
A retrospective study was performed including 230 patients diagnosed with stage 
II colorectal adenocarcinoma subjected to curative surgery in Centro Hospitalar S. João, 
Porto, Portugal, between January 2002 and December 2010. More patients were initially 
enrolled but were excluded, namely if they: 1) were less than 18 years old; 2) were lost 
to follow-up; 3) were incorrectly staged; 4) died of post-operative complications; 5) had 
more than one type of cancer; 6) had a relapse during the first 6 months after surgery. 
Patients for whom clinical information could not be collected were also excluded, as well 
as patients without or with insufficient tumor tissue available. Clinicopathological 
features collected included date of diagnosis, age at diagnosis, gender, clinical 
presentation at diagnosis with obstruction or intestinal perforation, tumor location, TNM 
stage, histological type, grade of differentiation, number of ganglia removed at surgery, 
vascular, lymphatic or perineural invasion, administration of adjuvant chemotherapy, 
chemotherapy scheme, date and site of relapse, date of death and cause of death 
(colorectal cancer-related or -unrelated). The tumor tissue was previously processed as 
part of the diagnostic routine following resective surgery. For immunohistochemistry 
analyses, 2mm diameter cores from the formalin-fixed, paraffin-embedded (FFPE) tissue 
were organized in tissue microarrays (TMA). 
 
3.1.1. DNA extraction from paraffin-embedded tissues 
Haematoxylin and eosin (HE) staining was performed to guarantee that specimens 
tested contained >20% cancer cells, and areas enriched in malignant cells were identified 
by a pathologist before DNA extraction. Two 10 μm slides for each sample were 
deparaffinized and then incubated for 10 minutes in absolute ethanol. Marked areas were 
macrodissected with a surgical blade from the two tissue sections. Genomic DNA was 
extracted with Cell Lysis solution (Citomed, Lisbon, Portugal) and digested with 
proteinase K 20mg/mL (Thermo Fisher Scientific, Massachusetts, USA) overnight at 
55ºC with agitation. Proteins were then precipitated with Protein Precipitation solution 
(Citomed, Lisbon, Portugal) and discarded following centrifugation at 16,000 g for 3 min 
at 4ºC. Isopropanol and glycogen were added to the genomic fraction in order to 
precipitate the DNA. After a centrifugation step at 16,000 g for 3 min, supernatant was 
carefully discarded, and the pellet washed with ethanol. Pellets were rehydrated with 
autoclaved deionized water and stored at -20 °C until use. The concentration of the 
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extracted DNA was assessed using a Nano-Drop 1000 instrument (Thermo Fisher 
Scientific, Massachusetts, USA). 
 
3.1.1.1. Characterization of BRAFV600E mutation 
Primary tumors were assessed for the presence of the BRAFV600E mutation in 
genomic DNA extracted from the paraffin-embedded tissues. DNA was amplified with 
the Taq PCR Master Mix Kit (Qiagen, Hilden, Germany) using the forward primer, 5’-
GGAAAGCATCTCACCTCATCC-3’, and the reverse, 5’-
AACTCAGCAGCATCTCAGGGC-3’, designed for the exon 15 of the BRAF gene 
(Sigma-Aldrich, Missouri, EUA). Sterilized water was included as template negative 
control. PCR amplification was performed as following: an initial activation step at 95ºC 
for 15 min, three denaturation cycles at 95 ºC for 30s, a first 8-cycle stage, including 
denaturation at 95 ºC for 30 s, annealing with touchdown temperature of 65ºC to 57ºC for 
90 s and extension at 72ºC for 1 min, then an additional 32-cycle stage, including 
denaturation at 95 ºC for 30 s, annealing at 60ºC for 30 s and extension at 72ºC for 1 min, 
and a final step of extension for 10 min at 72ºC. PCR products were analysed in 2% 
agarose gel and stained with GelRed (Intron Biotechnology, South Korea) in order to 
confirm the presence of the expected 200 bp fragment.  
PCR products were purified using the ExoSAP-IT Express PCR Product Cleanup 
reagent (Applied Biosystems, California, EUA) and sequencing reactions were run using 
the BigDye Terminator v3.1 cycle sequencing Kit (Applied Biosystems, California, 
EUA) according to manufacturer’s instructions. Sequencing reaction products using both 
forward and reverse primers were purified with Sephadex (GE Healthcare, Illinois, EUA) 
and mixed with formamide. Sanger sequencing of all PCR products was subsequently 
conducted on an Applied Biosystems 3500 Genetic Analyzer (Thermo Fisher Scientific, 
Massachusetts, USA) and sequences were analysed with Applied Biosystems Quality 
Check software (Thermo Fisher Cloud). Tumors with the BRAFV600E mutation were 
classified as mutant BRAF (versus wild-type). 
 
3.1.2. Immunohistochemical analysis of CDX2, SOX2 and SOX9 expression 
on TMA 
3µm thick sections of the TMAs were subjected to immunohistochemistry for 
CDX2, SOX2 and SOX9, following standard methodologies and Camilo et al., 2014. 
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Briefly, after deparaffination in xylene for 10 min and rehydration, heat-induced epitope 
retrieval was carried out in an IHC-Tek Epitope Retrieval Steamer Set for 40 min with 10 
mM citrate buffer, pH 6.0 (CDX2) or 10 mM, pH 8.0 EDTA (SOX2 and SOX9). 
Incubation with primary antibodies for CDX2 (1:50 dilution, CDX2-88 clone, Biogenex, 
California, USA), SOX2 (1:50 dilution, SP76 clone, Cell Marque, California, USA), and 
SOX9 (1:6000 dilution, AB5535, Millipore, Merck group, Darmstadt, Germany) was 
performed overnight, at 4°C. Sections were then incubated with a biotin-labelled rabbit 
anti-mouse secondary antibody, followed by the avidin/biotin-peroxidase detection 
system (Vectastain ABC kit, Vector Laboratories, California, USA). Detection was done 
using the Dako REAL™ Envision™ Detection System Peroxidase/DAB+ (DAKO, 
Glostrup, Denmark) according to the manufacturer’s instructions. Detection of expression 
was performed with 3,3′-diaminobenzidine (DAB) (Sigma-Aldrich, Missouri, USA) and 
tissue sections were counterstained with Gill’s haematoxylin (Leica Microsystems, 
Bucks, UK), then dehydrated, clarified and mounted. Normal colonic mucosa was used 
as a positive control for CDX2 and SOX9 expression and normal gastric mucosa for 
SOX2 expression. 
 
3.1.3. Immunohistochemical analysis of MLH1, MSH2, MSH6 and PMS2 
expression on TMA 
Immunohistochemistry was carried out using antibodies for MLH1 (1:50 dilution, 
G168-728 clone, BD Pharmingen, New Jersey, EUA), MSH2 (Pre-diluted, 25D12 clone, 
Leica Biosystems, Wetzlar, Germany), MSH6 (1:500, PU29 clone, Leica Biosystems, 
Wetzlar, Germany), and PMS2 (1:100, MOR4G clone, Leica Biosystems, Wetzlar, 
Germany), and the Leica Polymer Refine Detection kit on a Leica Bond-III Automated 
immunohistochemistry stainer (Leica Microsystems, Wetzlar, Germany). The antigen 
retrieval for these four proteins was carried out for 20 min in Er2 (similar to EDTA 
pH=8.0). 
 
3.2. Functional assays in colon carcinoma cell lines  
3.2.1. Cell line culture  
Human colorectal carcinoma cell line - SW620 (ATCC) - was grown in 
Dulbecco’s minimal essential medium (DMEM) (Thermo Fisher Scientific, 
Massachusetts, EUA) supplemented with 10% inactive fetal bovine serum (FBS) 
(Invitrogen, California, EUA) and 1% antibiotics (100 U/ml penicillin and 100 μg/ml 
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streptomycin) (Thermo Fisher Scientific, Massachusetts, EUA), and maintained at 37°C 
in a humidified 5% CO2 incubator.  
 
3.2.2. Determination of the IC50 for 5-FU 
First, 2x104 cells from SW620 cell line were seeded in a 96-well plate. For IC50 
determination, six different 5-FU (Sigma-Aldrich, Germany) concentrations, ranging 
from 1,06 to 34 μg/mL, in subsequent multiples of 2, were used to treat cells. Cells treated 
with only DMSO (Sigma-Aldrich, Germany) were used as control for treatment efficacy. 
After 48h incubation, cells were washed once with PBS 1x and then 50μL of PrestoBlue 
Viability Reagent 1x (Invitrogen, California, USA) was added in the dark to each well. 
The plates were incubated at 37ºC for 45 min in a humidified 5% CO2 incubator. The 
fluorescence of all wells was read both at 560nm (excitation) and 590nm (emission) for 
normalization. 
  
3.2.3. Overexpression and knock-down of SOX2 
1x105 cells were seeded in a 24 well plate. 24h later, transient transfection was 
performed using Lipofectamine 2000 (Thermo Fisher Scientific, Massachusetts, USA) 
with a mix of three small interfering RNAs (siRNAs) targeting SOX2 in a total 
concentration of 99.6 nM and with a non-targeting scrambled siRNA (Thermo Fisher 
Scientific, Massachusetts, USA), used as a negative control (Thermo Fisher Scientific, 
Massachusetts, USA), in a 1:1 ratio. The siRNAs and the Lipofectamine were diluted in 
Opti-MEM (Thermo Fisher Scientific, Massachusetts, USA) prior to the utilization. The 
cells were incubated at 37°C in a CO2 incubator and the efficiency of the siRNA silencing 
was evaluated 72h after transfection by real-time PCR and Western-blot.  
For SOX2 overexpression, cells were equally seeded in a 24-well plate and after 
24h were transfected with 1 μg of a human SOX2 expression vector containing two 
FLAG tags at the N-terminus or the corresponding empty vector in a ratio of 1:1.5 
relatively to Lipofectamine 2000 reagent, previously diluted in Opti-MEM medium 
(Thermo Fisher Scientific, Massachusetts, EUA). Cells were incubated at 37°C in a CO2 
incubator and the efficiency of the SOX2 overexpression was evaluated 72h after 
transfection by real-time PCR and Western blot. 
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3.2.4. 5-FU treatment and viability assays 
24h after transfection, cells were treated with a 5-FU dose corresponding to the 
IC50 - 7.7 μg/mL - for SW620. 
After 48h, cells were washed once with PBS 1x and then 50uL of PrestoBlue 
Viability Reagent 1x (Invitrogen, California, EUA), diluted in culture medium, was added 
in the dark to each well with cells and to another three additional wells with no cells, to 
use as background subtraction. The reaction was allowed to proceed for 45 min at 37ºC 
in a CO2 incubator. The fluorescence of all wells was read both at 560nm (excitation) and 
590nm (emission) for normalization. 
In addition, Sulforhodamine B (Sigma-Aldrich, Germany) viability assay was 
performed for comparison. For that, 50μL of PBS 1x were added to each well and then 
cells were fixed by adding 25 μL of Trichloroacetic Acid (TCA) 50%. Plates were 
incubated for 1h at 4ºC and then rinsed several times with deionised water and left to air 
dry.  
When completely dried, 50 μL of Sulforhodamine B solution 0.4% was added to 
each well and cells were stained for 30 min before quickly rinsing the plates 3 times with 
1% acetic acid. Plates were left to dry and after no moisture was visible, 100 μL of Tris 
Base Solution 10 mM were added to each well and the absorbance was measured at a 
wavelength of 510 nm. The results are expressed as means ± SD of representative 
triplicates. 
 
3.2.5. Annexin V/PI assay 
Apoptosis was evaluated using the Annexin V Apoptosis detection Kit 
(eBioscience, SanDiego CA, USA). Briefly, cells were trypsinized and resuspended in 
binding buffer (previously diluted in water, according to manufacturer’s instructions). 
Cells were incubated with Annexin V, in the dark, for 10 minutes at room temperature 
and then with propidium iodide. Apoptosis was quantified using the flow cytometer BD 
Accuri C6 and respective software (BD Biosciences, San Jose CA, USA). 
 
3.2.6. Protein extraction and Western-Blot 
To analyse SOX2 expression in the SW620 normal and transient transfected cells 
after 72h, cells were washed with cold PBS buffer and incubated on ice for 30 min with 
cold RIPA buffer - 50 mM Tris-HCl pH=7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 
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0.1% SDS (Sigma-Aldrich, California, EUA) supplemented with Complete protease 
inhibitor cocktail (Roche Applied Science, Indianapolis, USA), 1 mM PMSF and 1 mM 
Na3VO4. After the incubation period, cells were scraped, and the mixture was centrifuged 
at 14000 rpm for 15min at 4°C.  
The soluble proteins concentration was estimated using Pierce BCA protein Assay 
Kit (Thermo Fisher Scientific, Massachusetts, USA) according to manufacturer’s 
instructions, but only 20 µg of total protein extract were used for Western blot analysis. 
Proteins were separated in a 10% sodium dodecyl sulphate–polyacrylamide gel 
electrophoresis and transferred to a nitrocellulose membrane (Amersham, GE Healthcare, 
UK).  The membrane was stained with Ponceau Red (Sigma), to monitor transfer 
efficiency. Next, the membrane was incubated for 1 hour with the blocking solution, in 
this case, 5% non-fat milk in TBS (GRISP, Porto, Portugal) -1% Tween-20 (Sigma-
Aldrich, Missouri, EUA), and then blotted overnight at 4°C with the SOX2 primary 
antibody (1:250 dilution, Cell Marque, SP76 clone, rabbit, 34 kDa) in 5% non-fat milk in 
TBS-1% Tween-20. On the following day, the membrane was washed three times with 
TBS-1% Tween-20 to remove the unbound primary antibody. Then, the membrane was 
blocked for 1 hour with the secondary antibody anti-rabbit IgG (1:2,000 dilution, goat, 
Santa Cruz Biotechnology) in 5% non-fat milk in TBS-1% Tween-20 and washed three 
times TBS-1% Tween-20. The signal detection was performed using ECL detection kit 
(GE Healthcare, Illinois, EUA).  The loading control used was GAPDH (glyceraldehyde-
3-phosphate dehydrogenase). Membrane was first incubated overnight with the primary 
antibody for GADPH (1:10,000 dilution, mouse, Santa Cruz Biotechnology), then, after 
3 consecutive washes, incubated for 1h with the secondary antibody anti-mouse IgG 
(1:10,000 dilution, goat, Santa Cruz Biotechnology), then washed again, and finally 
revealed using ECL detection kit.  
 
3.2.7. RNA extraction and Real-time PCR  
Cells from each well were lysed in 300 μL of Lysis Buffer, containing 1/100 β-
mercaptoethanol, for approximately 30 minutes until cells were totally detached from the 
well. Total RNA was extracted using the Purelink RNA Mini Kit (Thermo Fisher 
Scientific, Massachusetts, USA) according to manufacturer’s instructions. This protocol 
includes a PureLink DNase Treatment, in which DNA is removed from RNA that is 
bound to a Spin Cartridge. After extraction, the purified RNA was stored at -80°C, until 
RNA concentration was measured using a Nano-Drop 1000 instrument (Thermo Fisher 
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Scientific, Massachusetts, USA). RNA was reverse transcribed to cDNA using the 
SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific, Massachusetts, USA), 
according to manufacturer’s instructions. SOX2 and 18S genes were amplified with 
SYBR Green (Thermo Fisher Scientific, Massachusetts, USA) using the following 
primers (SOX2: 5ʹ-AACGGCTCGCCCACCTACAGC-3ʹ, 5ʹ-
AGTGGGAGGAAGAGGTAACC-3ʹ; 18S: 5ʹ-CGCGCGCTAGAGGTGAAATTC-3ʹ; 
5ʹ-CATTCTTGGCAAATGCTTTCG-3ʹ; Camilo et al., 2012) in a fluorescence reader 
ABI Prism 7500. 10 ng of cDNA were used as template for each real-time PCR with 10 
µL SYBR Green and 0.3 μM of specific forward and reverse primers, in a final volume of 
20 µL. The following real-time PCR protocol has been applied: a denaturation step at 95 
ºC for 10 min, a 40-cycle stage, including denaturation at 95 ºC for 15 s and annealing at 
60ºC for 1 min, and a melting curve program (60–95ºC) with continuous fluorescence 
measurement. The amount of SOX2 mRNA was determined using the threshold cycle 
(Ct) values and ΔΔCt method (Livak et al., 2001). The levels of 18S were used for 
normalization of target gene abundance and relative mRNA levels were calculated. 
Reactions containing water instead of template were included as negative controls. The 
results are expressed as means ± SD using triplicates. 
 
3.3. Statistical Analysis 
This study followed the REMARK guidelines to report biomarkers (McShane et 
al., 2005). In order to assess the significance (P-values) of differences in 
clinicopathological features across different groups in our cohort, we have used different 
statistical tests. The t student test was used when comparing with age. The Qui-square 
(χ2) test was used for all the other variables. The Kaplan-Meier method was used to 
generate 5-year DFS and OS plots and its significance was assessed by the log-rank test. 
Differences were considered statistically significant when P value <0.05. Statistical 
analysis was performed in IBM SPSS Statistics version 24. In the functional assays in 
colon carcinoma cell lines each experiment was carried out in triplicates at least two 
times, and data was expressed as means ± SD. Statistical analysis was performed using 
Student’s t-test. A P< 0.05 was considered as significantly different. 
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IV. Results 
4.1 Cohort characterization  
Table 2 shows the clinicopathological features of all 230 patients diagnosed with 
stage II CRC included in the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency (n) Percentage (%) 
Patients 230 
 
Age (years)  
  Media 68.2 (±11.6) 
  Range 23-92 
Gender   
Female 93 40.4 
 Male 137 59.6 
Histopathological grade   
G1 4 1.7 
 G2 160 69.6 
G3 8 3.5 
ND 58 25.2 
Tumor Location   
Proximal colon 75 32.6 
Distal colon 105 45.7 
Rectum 47 20.4 
ND 3 1.3 
Location of Relapse   
Peritoneum 4 1.7 
Lung 3 1.3 
Liver 20 8.7 
Lymph nodes 3 1.3 
Local 12 5.2 
ND 9 3.9 
Chemotherapy   
Neo-Adjuvant   
Yes 13 5.7 
No 217 94.3 
Adjuvant   
Yes 35 15.2 
No 189 82.2 
ND 6 2.6 
Resection margins   
R0 179 77.8 
 R1/R2 2 0.9 
 ND 49 21.3 
Microsatellite instability   
MSI 92 40.0 
MSS 120 52.2 
ND 18 7.8 
BRAF V600E   
Wt 187 81.3 
Mut 30 13.0 
ND 13 5.7 
CDX2   
Yes 33 14.3 
No 197 85.7 
SOX2   
Yes 36 15.7 
No 194 84.3 
SOX9   
Yes 205 89.1 
No 25 10.9 
Table 2. Clinicopathological data for a series of 230 patients with stage II colorectal carcinoma.  
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Figure 8. Kaplan-Meyer survival analysis showing OS (A) and DFS (B) for 230 stage II colorectal cancer 
patients 5 years after diagnosis.  
Figure 9. Kaplan-Meyer survival analysis showing OS (A) and DFS (B) for 224 stage II colorectal cancer 
patients according to different treatment options – treated or not with adjuvant chemotherapy. Note. ACT 
stands for Adjuvant Chemotherapy.  
The median age in this retrospective series was 68.2 years (range, 23-92). Among 
the 230 patients, 137 (59.6%) were men and 93 (40.4%) were women. Concerning tumor 
grade, 4 tumors (1.7%) were well-differentiated (G1), 160 (69.6%) moderately 
differentiated and 8 (3.5%) were poorly differentiated. Seventy-five (32.6%) tumors were 
located proximally (right colon), 105 (45.7%) were located distally (left colon) and 47 
(20.4%) were in the rectum. Most relapses occurred in the liver (8.7%) and most patients 
(77.8%) had the resection margin free of cancer cells. Regarding treatment, 13 (5.7%) 
tumors (all rectal) received neo-adjuvant therapy and only 35 (15.2%) patients received 
adjuvant therapy.  
In this patient cohort, 80.8% of patients were alive 5 years after diagnosis and 
20.6% of the patients had relapse (see Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
In this stage II CRC series, adjuvant chemotherapy significantly improves patient 
OS but not DFS (Figure 9). 
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Figure 10. Analysis of MLH1 protein expression in 212 stage II colorectal carcinomas by 
immunohistochemistry. Positive (A) and negative (B) stain.  
4.2. Evaluation of putative biomarkers of CRC  
4.2.1. Microsatellite Instability (MSI)  
4.2.1.1 Immunohistochemical analysis of MMR (mismatch repair) protein 
expression on TMA 
Microsatellite instability was analysed using immunohistochemistry of MMR 
proteins: MLH1 (Figure 10), MSH2 (Figure 11), MSH6 (Figure 12) and PMS2 (Figure 
13) to infer MSI status of 212 patients. The rest of the cases were unevaluable due to 
insufficient number of epithelial tumor cells or loss of tissue on the TMA slide.  
MLH1 expression was observed in 131/212 (61.8%) tumors and 81/212 (38.2%) 
showed loss of expression of this protein (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MLH1 POSITIVE MLH1 NEGATIVE (A) (B) 
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Figure 11. Analysis of MSH2 protein expression in 212 stage II colorectal carcinomas by 
immunohistochemistry. Positive (A) and negative (B) stain.  
Figure 12. Analysis of MSH6 protein expression in 212 stage II colorectal carcinomas by 
immunohistochemistry. Positive (A) and negative (B) stain.  
 
Regarding MSH2 expression, 198/212 (93.4%) patients were positive and 14/212 
(6.6%) were negative (Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MSH6 expression was found in 170/212 (80.2%) of tumors and absent in the other 
42/212 (19.8%) (Figure 12). 
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Figure 14. Kaplan-Meyer survival analysis showing the probability of DFS for 212 patients according to MSI 
status.  
Figure 13. Analysis of PMS2 protein expression in 212 stage II colorectal carcinomas by 
immunohistochemistry. Positive (A) and negative (B) stain.  
 
Finally, concerning PMS2 expression, 174/212 (82.1%) of the tumors were 
positive whereas 38/212 (17.9%) were negative (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In summary, 120 (52.2%) patients were MSS based on the fact that they have not 
lost the expression of any of the four proteins, and 92 (40.0%) patients were MSI, being 
39 (17%) MSI-Low since they have lost the expression of only one MMR gene, and 53 
(23.0%) were MSI-High since they have lost the expression of at least two MMR genes. 
 
4.2.1.2. Correlation between MSI status and patient outcome 
In our patient cohort MSI did not show any relevance as prognostic (see Figure 
14; Supplementary Figure 1) or predictive (see Figure 15) biomarker.  
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Figure 15. Kaplan-Meyer survival analysis showing the probability of DFS for stage II CRC patients when 
treated with adjuvant chemotherapy (A) or not (B) according to MSI status. Note. ACT stands for Adjuvant 
Chemotherapy. 
 
 
 
 
 
 
 
 
 
 
4.2.2. BRAFV600E mutation 
4.2.2.1. BRAFV600E mutation analysis by sequencing 
BRAFV600E mutation status was accessed in 217 patients. In the rest of the tumors 
the material was insufficient for DNA extraction. In our cohort, BRAFV600E mutation was 
present in 30 (13.0%) tumors versus 187 (81.3%) that were wild type (see Figure 16). 
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Figure 16.  BRAF sequencing electropherograms in respect to BRAFV600E mutation: (A) wild-type; (B) 
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Figure 17. Kaplan-Meyer survival analysis showing the probability of DFS for 217 patients according to 
BRAFV600E status.  
Figure 18. Kaplan-Meyer survival analysis showing the probability of DFS for stage II CRC patients when 
treated with adjuvant chemotherapy (A) or not (B) according to BRAFV600E mutation Notes. ACT stands for 
Adjuvant Chemotherapy. 
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4.2.2.2 Correlation between BRAFV600E mutation status and patient outcome 
In this series, BRAFV600E mutation did not show any relevance as prognostic (see 
Figure 17; Supplementary Figure 2) or predictive (see Figure 18) biomarker.  
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Figure 19. Analysis of CDX2 expression in normal intestine epithelium by immunohistochemistry. 
Figure 20. Analysis of CDX2 protein expression in 230 stage II colorectal carcinomas by 
immunohistochemistry. Positive (A) and negative (B) stain.  
4.2.3. CDX2 expression 
4.2.3.1. Immunohistochemical analysis of CDX2 protein expression on TMA 
Analysis of CDX2 expression was performed by immunohistochemistry in all 230 
tumors. Expression in the normal intestine epithelium is shown in Figure 19. CDX2 loss 
of expression was observed in 33 (14.3%) of patients compared to the other 197 (85.7%) 
that showed a strong staining (Figure 20).  
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Figure 21. Kaplan-Meyer survival analysis showing the probability of DFS for 230 patients according to 
CDX2 expression.  
Figure 22. Kaplan-Meyer survival analysis showing the probability of DFS for stage II CRC patients when 
treated with adjuvant chemotherapy (A) or not (B) according to CDX2 expression. Note. ACT stands for 
Adjuvant Chemotherapy. 
 
4.2.3.2. Correlation between CDX2 expression and patient outcome 
In our patient cohort CDX2 loss of expression did not show any relevance as 
prognostic (see Figure 21; Supplementary Figure 3) or predictive (see Figure 22) 
biomarker. 
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SOX2 EXPRESSION IN NORMAL INSTESTINAL MUCOSA 
Figure 23. Analysis of SOX2 expression in normal intestine epithelium by immunohistochemistry. 
Figure 24. Analysis of SOX2 protein expression in 230 stage II colorectal carcinomas by 
immunohistochemistry. Positive (A) and negative (B) stain.  
 
4.2.4. SOX2 expression 
4.2.4.1. Immunohistochemical analysis of SOX2 protein expression on TMA  
Analysis of SOX2 expression was performed by immunohistochemistry in all 
230 tumors. SOX2 is not expressed in the normal intestine epithelium as shown Figure 
23. SOX2 de novo expression was observed in 36 (15.7%) patients compared to the 
other 194 (84.3%) that showed no staining (see Figure 24).  
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Figure 25. Kaplan-Meyer survival analysis showing the probability of DFS for 230 patients according to SOX2 
expression.  
Figure 26. Kaplan-Meyer survival analysis showing the probability of DFS for stage II CRC patients when 
treated with adjuvant chemotherapy (A) or not (B) according to SOX2 expression. Note. ACT stands for 
Adjuvant Chemotherapy. 
 
4.2.4.2. Correlation between SOX2 expression and patient outcome 
In our patient cohort, SOX2 de novo expression did not show any relevance as 
prognostic biomarker (Figure 25, Supplementary Figure 4).  
 
 
 
  
 
 
 
 
 
 
 
However, SOX2 positive patients treated with adjuvant chemotherapy had 
significantly higher probability of relapse after 5 years than SOX2 negative patients 
treated with adjuvant chemotherapy (Figure 26). 
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Figure 27. Kaplan-Meyer survival analysis showing the probability of DFS for SOX2 negative (A) and SOX2 
positive (B) stage II CRC patients according to having received or not adjuvant chemotherapy. Note. ACT 
stands for Adjuvant Chemotherapy. 
  
 
 
Furthermore, SOX2 positive patients respond poorly to adjuvant chemotherapy 
having a tendency, borderline significant (P=0.06) of lower DFS than SOX2 positive 
patients not treated with adjuvant treatment (see Figure 27). On the other way around, 
SOX2 negative patients treated with adjuvant chemotherapy have a significantly higher 
probability of DFS survival that SOX2 negative patients that did not receive adjuvant 
therapy. (see Figure 27). 
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Figure 28. Analysis of SOX9 expression in normal intestine epithelium by immunohistochemistry.   
Figure 29. Analysis of SOX9 protein expression in 230 stage II colorectal carcinomas by 
immunohistochemistry.  Positive (A) and negative (B) stain.  
 
4.2.5. SOX9 expression 
4.2.5.1. Immunohistochemical analysis of SOX9 protein expression on TMA  
Analysis of SOX9 expression was performed by immunohistochemistry in all 230 
tumors. SOX9 expression pattern in the normal intestine epithelium is shown in Figure 
28. SOX9 loss of expression was observed in 25 (10.9%) patients compared to the other 
205 (89.1%) that showed a strong staining (see Figure 29).  
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Figure 30. Kaplan-Meyer survival analysis showing the probability of DFS for 230 patients according to SOX9 
expression. 
Figure 31. Kaplan-Meyer survival analysis showing the probability of DFS for stage II CRC patients when 
treated with adjuvant chemotherapy (A) or not (B) according to SOX9 expression. Notes. ACT stands for 
Adjuvant Chemotherapy. 
 
(B) 
 
4.2.5.2. Correlation between SOX9 expression and patient outcome 
In our patient cohort, SOX9 loss of expression did not show any relevance as a 
prognostic (see Figure 30; supplementary Figure 5) or predictive (see Figure 31) 
biomarker.  
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Figure 32. Kaplan-Meyer survival analysis showing the probability of DFS for 25 SOX9 negative patients, 
according to SOX2 expression.  
 
Interestingly, when analysing the expression of more than one molecule and 
patient outcome, we noticed that in patients with SOX9 negative tumors, those that are 
SOX2 positive have a significantly lower DFS when compared to SOX2 negative (see 
Figure 32).  
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4.2.6 Clinicopathological data association with the different putative biomarkers  
In Table 3 and Table 4 we correlated the clinicopathological data for all patients 
and the putative biomarkers studied. 
 
 
 
 Microsatellite Instability BRAF
V600E 
MSS(%) MSI(%) P WT(%) MUT(%) P 
Age (years)       
Media 69.0±11.3 66.6±12.3 
0.13 
67.6±11.6 72.9±8.8 
0.02 
Range 35-91 23-92 23-92 55-87 
Gender        
Female 35.8 64.2 
0.16 
78.2 21.8 
0.01 
Male 60.6 39.4 91.5 8.5 
Histopathological grade        
G1 50.0 50.0 
0.29 
100.0 0.0 
0.18 G2 55.4 44.6 84.4 15.6 
G3 20.0 80.0 62.5 37.5 
Tumor Location       
Proximal colon 50.0 50.0 
0.29 
77.8 22.2 
0.05 Distal colon 58.8 41.2 86.3 13.7 
Rectum 64.4 35.6 100.0 0.0 
Microsatellite instability       
MSI 
 
85.7 14.3 
1.00 
MSS 85.4 14.6 
BRAFV600E       
Wt 55.8 44.2 
1.00  
Mut 55.2 44.8 
CDX2       
Positive 61.7 38.3 
<0.001 
87.6 12.4 
0.17 
Negative  24.1 75.9 78.1 21.9 
SOX2       
Positive 65.6 34.4 
0.33 
90.3 9.7 
0.58 
Negative  55.0 45.0 85.5 14.5 
SOX9       
Positive 58.7 41.3 
0.08 
85.7 14.3 
0.75 
Negative  39.1 60.9 90.5 9.5 
Notes. P values (statistical significance threshold<0.05) were obtained using Student’s t test for the 
continuous variable and Qui-square (χ2) test for categorical variables; comparisons with P<0.05 are indicated 
in bold face. 
Table 3. Clinicopathological data association with MSI and BRAFV600E status in 230 patients with stage II 
colorectal carcinoma. 
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Table 4. Clinicopathological data association with CDX2, SOX2 and SOX9 expression in all patients included 
in the study. 
 
 
 
 
 
 
 
 
 
 CDX2 SOX2 SOX9 
+ - P + - P + - P 
Age (years)          
Media 68.3±11.6 67.7±11.8 
0.80 
68.9±11.5 68.1±11.6 
0.68 
68.2±11.3 68.1±13.8 
0.96 
Range 23-92 35-87 37-87 23-92 23-91 35-92 
Gender           
Female 20.4 79.6 
0.04 
16.1 83.9 
0.86 
87.1 12.9 
0.52 
Male 89.8 10.2 15.3 84.7 90.5 9.5 
Histopathological 
grade  
         
G1 100.0 0.0 
<0.001 
25.0 75.0 
0.01 
100.0 0.0 
0.78 G2 86.2 13.78 12.5 87.5 90.0 10.0 
G3 25.0 75.0 50.0 50.0 87.5 12.5 
Tumor Location          
Proximal colon 78.7 21.3 
0.07 
17.3 82.7 
0.11 
85.3 14.7 
0.30 Distal colon 86.7 13.3 10.5 89.5 92.4 7.6 
Rectum 93.6 6.4 23.4 76.6 87.2 12.8 
Microsatellite 
instability 
         
MSI 76.1 23.9 
<0.001 
12.0 88.0 
0.33 
84.8 15.2 
0.08 
MSS 94.2 5.8 17.5 82.5 92.5 7.5 
BRAFV600E          
Wt 86.6 13.4 
0.17 
15.0 85.0 
0.58 
89.8 10.2 
0.75 
Mut 76.7 23.3 10.0 90.0 93.3 6.7 
CDX2 
 
      
Positive 15.2 84.8 
0.61 
91.4 8.6 
0.01 
Negative  18.2 81.8 75.8 24.2 
SOX2 
 
   
Positive 83.3 16.7 
0.61 
88.9 11.1 
1.00 
Negative  86.1 13.9 89.2 10.8 
SOX9    
 Positive 87.8 12.2 
0.01 
15.6 84.4 
1.00 
Negative  68.0 32.0 16.0 84.0 
Notes. P values (statistical significance threshold<0.05) were obtained using Student’s t test for the 
continuous variable and Qui-square (χ2) test for categorical variables; comparisons with P<0.05 are indicated 
in bold face. 
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MSI did not correlate with any of the clinicopathological parameters, which 
included age at diagnosis, gender, histopathological grade and tumor location. However, 
microsatellite stable tumors were significantly associated with CDX2 positive expression 
(P<0.001).  
BRAFV600E mutation correlated with older age at time of diagnosis. Patients 
harboring the mutation are diagnosed about 5 years later than patients that are wild type 
for this mutation (72.9±8.8 versus 67.6±11.6; P=0.02). Also, this mutation was 
significantly more common in female than in male patients (P=0.01) and borderline 
significant in proximal colon (P=0.05). This mutation was not found in the rectal tumors.  
CDX2 loss of expression was more common in females (P=0.04) and it correlated 
strongly with poorly differentiated tumors (P<0.001). CDX2 expression was not 
associated with other clinicopathological parameters. Moreover, CDX2 loss of expression 
was significantly correlated with MSI status and was also significantly associated with 
SOX9 negative expression.  
SOX2 expression was only associated with poorly differentiated tumors (P=0.01).  
Finally, SOX9 expression did not correlate with any of the clinicopathological 
parameters studied. However, it did correlate with CDX2 expression, as previously 
described.  
 
4.3. Functional assays in SW620 colon carcinoma cell line 
Based on the results obtained in the patient series that suggested that SOX2 could 
be a predictive biomarker of resistance to chemotherapy and on previous results of the 
group in a modified colon cancer cell line (see supplementary Figure 6, 7 and 8), we 
decided to evaluate the viability of a colon cancer cell line - SW620 - treated with 5-FU, 
after up- and down-regulation of SOX2 expression.  
 
4.3.1. Determination of the IC50 of 5-FU in the SW620 colon cancer cell line 
With the purpose of evaluating the cytotoxicity of 5-FU in SW620 colon cancer 
cell line, the IC50 (half maximal inhibitory concentration) value was assessed by two 
different viability assays: a resazurin-based method (Presto Blue) that measures 
metabolically active cells, and Sulforhodamine assay that quantifies protein content 
(Table 5). 
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4.3.2. SOX2 silencing and overexpression 
4.3.2.1. Western-blot analysis of SOX2 expression in normal and transiently 
transfected cells  
To confirm that we successfully silenced and overexpressed SOX2 in SW620 
colon cancer cell lines we performed a Western-blot to analyse SOX2 protein expression 
in normal and transiently transfected cells, 72h after transfection (Figure 33).  
 
SW620 
 
 
 
 
 
 
 
 
 
4.3.2.2. Real-Time PCR analysis of SOX2 mRNA expression in normal and 
transiently transfected cells  
Likewise, we extracted mRNA from normal and transient cells to perform Real-
Time PCR to analyse SOX2 mRNA expression 72h after transfection (Figures 34).   
 
 
Cell Line IC50 (μg/mL) 
SW620 7.72 
Figure 33. Western-blot analysis of SOX2 protein expression in SW620 wild-type and transfected cells. (A) 
Detection of SOX2 protein expression in wild-type SW620 cells as in negative control of the silencing, a 
scrambled siRNA (SC), and also in transiently transfected cells with siRNA for SOX2 (siRNA SOX2). (B) 
Detection of SOX2 protein expression in wild-type SW620 cells as in negative control of the overexpression, 
an empty vector (pcDNA 3.1), and also in transiently transfected cells with pcDNA3.1 for SOX2 (pcDNA 3.1 
SOX2). 
 
GAPDH 
SOX2 
SOX2 
GAPDH 
(A) (B) 
Table 5. Value of IC50 in SW620 colon cancer cell line. 
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We were able to successfully silence and overexpress SOX2 in SW620.  
 
4.3.3. Viability assays in SW620 colon cancer cell line treated with 5-FU 
Unfortunately, when we compared the viability of SW620 cells in which SOX2 
was silenced or overexpressed, after treating SW620 cells with 5-FU (7.72μg/mL) 
(Supplementary Figure 9), we could not observe significative differences when 
compared with negative controls (Figure 35). 
 
 
 
 
 
Figure 35. Viability of the SW620 cells treated with 5-FU (A) after transient transfection with siRNA SOX2 
versus negative control (scrambled siRNA), or (B) after transient transfection with pcDNA3.1 SOX2 
overexpression vector versus negative control (empty vector). 
 
Figure 34. SOX2 mRNA expression comparison between WT and transfected SW620 cells. The values are 
normalized to SOX2 expression in negative controls. (A) silencing with siRNA SOX2 and (B) SOX2 
overexpression with pcDNA3.1. SOX2 vector.  Significant differences (***p<0.001).   
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(A) (B) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. Viability of the SW620 cells treated with 5-FU (A) after transient transfection with siRNA SOX2 
versus negative control (scrambled siRNA), or (B) after transient transfection with pcDNA3.1 SOX2 
overexpression vector versus negative control (empty vector). 
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V. Discussion 
 
5.1. Cohort characterization  
We investigated the prognostic and predictive value of five putative molecular 
biomarkers - microsatellite instability status, BRAFV600E mutation and CDX2, SOX2 and 
SOX9 expression - in a Portuguese cohort of 230 patients diagnosed with stage II 
colorectal cancer. In this series, the median patient age at time of diagnosis was 68 years 
old. This value is just slightly above that reported for the median age at time of diagnosis 
for all stages, in both men and women, worldwide, that is of 63 years old (American 
Cancer Society. Colorectal Cancer Facts & Figures, 2017-2019).  
In our cohort, 80.8% (186/230) of the patients were alive 5 years after diagnosis. 
This value is above the 71% OS reported for CRC patients diagnosed in early stages 
(American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019). In the same 
period, 20.6% of the patients relapsed which is a high number. Boland et al., 2016 also 
reported a high percentage of relapse of 20% in their stage II cohort. However, a recent 
multicentre study with several hundreds of stage II CRC patients reports less than 15% 
of relapse (Yamano et al., 2018). 
In our cohort the percentage of patients treated with adjuvant chemotherapy, in 
addition to surgery, was of 15.2% (35/230) being lower than the 20% to 59%, reported in 
different studies (O'Connor et al., 2011; Tsikitis et al., 2014; Grant et al., 2018, Yamano 
et al., 2018). This difference in administration of adjuvant treatment could partially 
explain the high percentage of recurrence and emphasizes the existence of an untreated 
subgroup of patients that is not selected by the current criteria. Chemotherapy seems to 
have a significant impact in patient OS however this result might be subjected to a bias 
since the use of adjuvant chemotherapy significantly correlates with younger age at time 
of diagnosis (57.6±11.6 years in treated versus 70.4±10.5; P<0.001 in untreated patients). 
When we compare the DFS of the patients treated or not with adjuvant chemotherapy, no 
significant differences are observed. This observation corroborates the urgent need of new 
biomarkers that could enhance the potential of current therapy in order to minimize the 
risk of recurrence.  
 
5.2. Microsatellite Instability (MSI)  
Microsatellite Instability was accessed by evaluating the expression of genes 
involved in MMR. According to the expression of MLH1, MSH6, MSH2 and PMS2, and 
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considering positive all the cases with expression regardless of the extension, we found 
40% of MSI tumors. This result is higher than expected since most of previous studies 
report approximately 20% of MSI cases in stage II CRC (reviewed in Boland et al., 2010; 
Puccini et al., 2017). However, the highest frequency described so far for a stage II CRC 
series was 57.9% (Moghbeli et al., 2011). MSI is more frequent in colon cancer when 
compared to the rectum (Hong et al., 2012). A study with only stage II colon cancer cases 
reported an MSI percentage of 34.1% (Grant et al., 2018). The higher frequency of MSI 
in this stage II CRC cohort could partially be explained by the fact that it is enriched in 
colon cancer cases. The expected proportion of rectal/colon cancers is 25% (American 
Cancer Society. Colorectal Cancer Facts & Figures, 2017-2019). In our cohort the 
percentage of rectal cancers is only 20.4%. 
Like in previous studies MLH1 was the most frequently mutated gene, (Herfarth 
et al., 1997; Kheirelseid et al., 2013) being its expression lost in 81/92 (88.0%) MSI 
patients. MSI has been extensively studied as a predictive biomarker in stage II CRC. In 
fact, clinicians are already recommending to not administrate adjuvant therapy to MSI 
patients, since they have good prognosis and do not benefit from it. However, in our study 
MSI status did not correlate with better DFS or OS and it did not have influence in 
response to therapy. Accordingly, in a clinical trial (QUASAR - Quick and Simple and 
Reliable) with 1913 patients, (95% of whom had stage II CRC) which were randomly 
assigned between 5-FU plus folinic acid and no chemotherapy, no evidence was found 
that patients with dMMR fail to respond to chemotherapy (Hutchins et al., 2011). 
Moreover, in two recent meta-analysis by Gkekas et al., 2017 and Romiti et al., 2017 it 
was also not found any value for MSI as a biomarker in stage II colon cancer. In addition, 
Kim et al., 2015 did not find any correlation between MSI and a better patient outcome 
but they report a significant correlation between MSS and better DFS, when compared to 
the MSI patients. 
Although very widely described the association between MSI and BRAF, it was 
not reproduced in our study. A possible explanation, though unexpected, could be that 
our series is enriched in hereditary forms of CRC. Lynch syndrome, the most common 
form of hereditary CRC is characterized by MSI phenotype (Thiel et al., 2013). The 
distinction between hereditary and sporadic MSI CRC is a crucial step in Lynch syndrome 
diagnoses. Within MSI colorectal cancers, the BRAFV600E mutation was strongly 
associated with sporadic origin (Capper et al., 2013). Indeed, BRAFV600E mutation in MSI 
colorectal carcinomas virtually excludes Lynch syndrome (Toon et al., 2013).  
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In what concerns associations between MSI status and the other putative 
biomarkers we have studied, the absence of CDX2 expression was much more common 
in the MSI tumours. CDX2 was already reported to be significantly positively correlated 
with the expression the proteins involved in DNA repair (Tóth et al., 2018). 
 
5.3. BRAFV600E mutation 
In our stage II CRC series, BRAF mutation was present in 30 (13%) patients, in 
accordance with previous reports in which this percentage varies between 4 and 18% 
(Cuyle et al., 2017). In rectal cancer, BRAFV600E mutation was reported as extremely rare 
(Tamas et al., 2015) and in our series none of the rectal cancer patients harboured this 
mutation. Like in previous studies, BRAFV600E strongly correlated with older age patients, 
female gender and tumour location in the proximal colon (de Cuba et al., 2016; Chen et 
al., 2016; Puccini et al., 2017).  
Since BRAF mutations are associated with older age, its value as a biomarker in 
early stage CRC is less well clarified (de Cuba et al., 2016). Like previous studies (Chen 
et al., 2016, French et al., 2008; Mouradov et al., 2013, André et al., 2015; Shen et al., 
2016) we did not find any prognostic value for BRAFV600E in our stage II CRC series. 
Also, our results agree with the former described lack of evidence for a predictive value 
for BRAFV600E in early stage CRC (Cuyle et al., 2017). 
 
5.4. CDX2 expression 
In what concerns the expression of CDX2, we found a downregulation of this 
intestinal transcription factor in 14.3% of patients. In prior studies loss of CDX2 is found 
in 4% (Dalerba et al., 2016) to 30% (Baba et al., 2009) CRC patients. Like in previous 
studies (Dawson et al., 2014; Olsen et al., 2015; Bruun et al., 2018), we did not find 
prognostic neither predictive value for CDX2 expression.  
CDX2 loss of expression was more often found in female patients, as already 
reported in Zhang et al., 2016. As well, low CDX2 expression correlated with poorly and 
moderately differentiated tumors in our series. This goes in hand with previous reports 
that correlate CDX2 loss of expression with poor differentiated tumors (Bakaris et al., 
2008; Olsen et al., 2015; Lundberg et al., 2016, Bruun et al., 2018). This would be 
expected since CDX2 is a major regulator of the intestine-specific genes involved in cell 
differentiation (Lundberg et al., 2016). 
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A decreased expression of CDX2 was, like in previous studies, closely linked to 
MSI (Lundberg et al., 2016; Schirripa et al., 2016; Olsen et al., 2015; Dawnson et al., 
2014). However, whether loss of CDX2 expression plays a particularly active role in 
tumour progression in MSI tumours remains to be elucidated (Olsen et al., 2015). 
 
5.5. SOX2 expression 
SOX2 is not expressed in the normal intestinal epithelium. Recently, it was 
reported that SOX2 is amplified in a variety of cancers (Du et al., 2016; Camilo et al., 
2015). We found de novo expression of SOX2 in 15.7% of the patients. SOX2 expression 
has been extensively associated with poor differentiation (Lundberg et al., 2014). In our 
CRC stage II series, SOX2 correlated also with poor differentiation. SOX2 expression 
has been reported to be associated with worse patient outcome, however there was 
significant heterogeneity between studies (Du et al., 2016). In our cohort, SOX2 
expression did not show any prognostic value. Moreover, SOX2 overexpression was 
reported to correlate with poorer OS in patients who did not receive adjuvant 
chemotherapy, but no differences were found between patients that received adjuvant 
therapy (Du et al., 2016). In our stage II CRC patient cohort, SOX2 de novo expression 
significantly correlated with worse DFS survival in patients who received adjuvant 
chemotherapy. This suggests that SOX2 positive patients could respond worse to therapy.  
SOX2 was expected to have an important role in CRC, since it is widely associated 
with stemness, growth and metastasis (Saigusa et al., 2009; Fang et al., 2010; Neumann 
et al., 2011; Zheng et al., 2017). The role we found for SOX2 as a predictive biomarker 
in early CRC is very promising. In a previous study by Yang et al., SOX2 was already 
reported to be expressed at higher levels in drug-resistant cells when compared to parental 
colon cancer cells.  
For further validation of SOX2 as a predictive biomarker of resistance to therapy, 
we evaluated the viability of a colon cancer cell line treated with 5-FU, after up- and 
downregulation of SOX2 expression. According to our results in the retrospective study 
we expected that SOX2 expression would increase the resistance of the cells to 5-FU, 
reducing the effectiveness of the 5-FU based adjuvant chemotherapy. So, in cells with 
SOX2 silencing, we expected less viability when treated with 5-FU. Similarly, when 
SOX2 is overexpressed, we expected cells to be more resistant and then be more viable 
after treatment with 5-FU. Unfortunately, we could not observe significant differences. 
In a different cellular model, with CDX2 knockdown using a genome-editing approach, 
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SOX2 becomes highly expressed. The cells from the CDX2 knock-out cellular model, 
which expressed high levels of SOX2, were more resistant to the 5-FU cytotoxicity. To 
confirm that SOX2 effectively plays a role in this observation we also compared LS174T 
CDX2-KO cells transfected with siRNA for SOX2 with parental ones. When SOX2 is 
downregulated by siRNA, cells become significantly more sensitive to 5-FU, leading to 
the conclusion that in fact the resistance is, at least partially, mediated by SOX2. At this 
point we argue that the different results could be due to the efficacy of transient 
transfection which does not guarantee a significant number of transfected cells to observe 
biological differences. 
 
5.6. SOX9 expression 
We found that SOX9 expression was lost in 10.9% of cases. It is very clear the 
stronger staining of SOX9 in the normal colonic epithelium in the proliferative lower half 
of the crypts of Lieberkuhn. This expression pattern was already noticed by Blache et al., 
2004 and Lu et al., 2008 who observed SOX9 also in the nuclei of the Paneth cells also 
located at the bottom of the crypts. In our stage II cohort, SOX9 did not have any 
prognostic neither predictive value. However, SOX9 negativity when associated with 
SOX2 positivity significantly correlated with worst DFS. SOX9 loss of expression was 
previously, reported to identify patients with worse prognosis in CRC (Espersen et al., 
2016) and SOX2 was also previously associated with worse patient outcome (Lundberg 
et al., 2014), 
SOX9 has been reported to be involved in the repression of differentiation genes 
including CDX2 (Blache et al., 2004; Subramanian et al. 1998; Sillberg et al., 2000) 
Interestingly, CDX2 expression was also associated with SOX9 expression in our stage 
II cohort, however, not as expected since CDX2 negative expression was more associated 
with SOX9 negative expression.  
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VI. Conclusions 
The main goal of this thesis was to evaluate the prognostic and predictive value 
of a panel of 5 molecules of interest in colorectal carcinogenesis in a Portuguese stage II 
CRC patient cohort. Namely, we investigated the value of microsatellite instability status, 
BRAFV600E mutation, and CDX2, SOX2 and SOX9 expression. 
In this CRC series, loss of CDX2 expression and de novo SOX2 expression 
significantly correlated with less tumour differentiation suggesting that modulation of 
these transcription factors contribute to tumour progression. SOX2 expression per se did 
not predict patient outcome but in combination with SOX9 loss of expression predicts 
tumour recurrence, which has not been reported so far. We would like to further 
investigate the combined effect of these two transcription factors in intestinal cellular 
models and to understand the molecular mechanisms involved. We could also test the 
tumor-initiation of these cells by carrying out in vitro tumorsphere formation assays and 
xenografts in nude mice. 
 Moreover, we identified for the first time SOX2 as a putative biomarker of 
response to adjuvant chemotherapy in stage II CRC patients. In patients treated with 
adjuvant chemotherapy, de novo SOX2 expression significantly correlated with increased 
risk of recurrence. This observation suggests that SOX2 might be involved in resistance 
to 5-FU based adjuvant chemotherapy. The in vitro experiments performed in this study, 
based on transient modulation of SOX2 expression did not allow to reinforce this 
conclusion. Different experiments are ongoing to modulate SOX2 expression using stable 
transfection assays to more accurately measure its influence in resistance to 
chemotherapy.  
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Supplementary Figure 1. Kaplan-Meyer survival analysis showing the probability of OS for 212 patients 
according to MSI status. 
Supplementary Figure 2. Kaplan-Meyer survival analysis showing the probability of OS for 217 patients 
according to BRAFV600E status.  
Supplementary Figure 3. Kaplan-Meyer survival analysis showing the probability of OS for 230 patients 
according to CDX2 expression.  
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Supplementary Figure 4. Kaplan-Meyer survival analysis showing the probability of OS for 230 patients 
according to SOX2 expression.  
(B) MSI 
Supplementary Figure 5, Kaplan-Meyer survival analysis showing the probability of DFS for MSS (A) and 
MSI (B) stage II CRC patients according to having received or not adjuvant chemotherapy.  
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Supplementary Figure 6. Western-blot analysis of SOX2 and CDX2 protein expression in LS174T WT and 
LS174T CDX2-KO (data obtained from a previous study done by the research group). 
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Supplementary Figure 7. Comparison between the apoptotic levels in LS174T WT and LS174T CDX2-KO 
cell lines. Cells were incubated 48h with 4μg/mL of 5-FU for 48h then double stained with annexin V and PI. 
Apoptosis analysis was performed by FACS. Results are mean ± SD. Significant differences (*p<0.05). Data 
obtained from a previous study done by the research group. 
 
Supplementary Figure 8. Comparison between the apoptotic level in LS174T CDX2-KO normal and 
transfected cells with siRNA for SOX2. Cells were incubated 48h with 4μg/mL of 5-FU for 48h then double 
stained with annexin V and PI. Apoptosis analysis was performed by FACS. Results are mean ± SD. Significant 
differences (*p<0.05). Data obtained from a previous study done by the research group. 
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Supplementary Figure 9. Microscopical observation (magnification 50x) of SW620 treated with 5-
FU versus DMSO, after SOX2 silencing and overexpression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
